Skip to Content

Neuren Pharmaceuticals Ltd NURPF

Morningstar Rating
$14.25 +0.51 (3.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NURPF is trading at a 418% premium.
Price
$14.18
Fair Value
$36.96
Uncertainty
Very High
1-Star Price
$17.90
5-Star Price
$5.36
Economic Moat
Ntdpl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NURPF is a good fit for your portfolio.

Trading Information

Previous Close Price
$13.74
Day Range
$14.2514.25
52-Week Range
$6.1717.21
Bid/Ask
$13.30 / $14.59
Market Cap
$1.85 Bil
Volume/Avg
207 / 1,306

Key Statistics

Price/Earnings (Normalized)
17.39
Price/Sales
12.11
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
8

Comparables

Valuation

Metric
NURPF
ITCI
VAXX
Price/Earnings (Normalized)
17.39
Price/Book Value
13.2212.703.31
Price/Sales
12.1114.69
Price/Cash Flow
Price/Earnings
NURPF
ITCI
VAXX

Financial Strength

Metric
NURPF
ITCI
VAXX
Quick Ratio
5.684.501.75
Current Ratio
5.785.121.89
Interest Coverage
−83.80
Quick Ratio
NURPF
ITCI
VAXX

Profitability

Metric
NURPF
ITCI
VAXX
Return on Assets (Normalized)
−9.15%−67.69%
Return on Equity (Normalized)
−10.98%−136.96%
Return on Invested Capital (Normalized)
−13.47%−101.16%
Return on Assets
NURPF
ITCI
VAXX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SmxsgbrsXgvg$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
KfcdwpwdHfkjpm$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
BlbrdfdzsQjlxyw$121.2 Bil
Moderna Inc
MRNA
FbqlkjltLybgt$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
FqyjqbkWmgqjy$33.0 Bil
argenx SE ADR
ARGX
RqqqtcbVzvp$27.9 Bil
BioNTech SE ADR
BNTX
TbmmbgnQrpx$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
TmjhrwwdDdfdhls$16.1 Bil
United Therapeutics Corp
UTHR
DxhtxjdFtrf$14.3 Bil
Incyte Corp
INCY
VpfrnlqhtSfntj$12.5 Bil

Sponsor Center